Radiopharm Reports Quarter-End Cash and Completes Two Financing Offers
Radiopharm reported $7.5 million in quarter-end cash, versus $4.1 million in the prior quarter, and $10.7 million in operating cash outflows. It completed an A$12.5 million placement and an A$3 million share purchase plan; the RAD101 Phase 3 trial is expected to initiate in 1Q27.
Radiopharm reported $7.5M in quarter-end cash, versus $4.1M in the prior quarter, and $10.7M in operating cash outflows. It completed an A$12.5M placement and A$3M share purchase plan, and expects the RAD101 Phase 3 trial to initiate in 1Q27.Material DetailsContext by AI AnalystThis is a clinical-s…